Direct oral anticoagulants (DOACs): benefits, limitations, and cost-effectiveness considerations in Thailand

Anthony P. Carnicelli, Hwanhee Hong, Stuart J. Connolly, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clin ical trials with interaction testing by age and sex. Circulation. 2022;145:242-55.

Atreja N, Johannesen K, Subash R, Bektur C, Hagan M, Hines DM, et al. US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total. J Comp Eff Res. 2024:e240163.

Peng K, Li Y, Chan EW, Wong ICK, Li X. Cost-effectiveness of direct oral anticoagulants in patients with nonvalvular atrial fibrillation in Hong Kong. Value Health Reg Issues. 2023;36:51-7.

Choi JH, Kim W, Kim YT, Cho J, Shin SY, et al. Cost-effectiveness of direct oral anticoagulant vs. warfarin among atrial fibrillation patients with intermediate stroke risk. Front Cardiovasc Mes. 2022;9:849474. doi: 10.3389/fcvm.20223849474.

Cameron Karnick, Ashley Modany, Molly McGraw. Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: a retrospective claims analysis. J Manag Care Spec Pharm. 2022;28:1304-15.

Law S, Ghag D, Grafstein E, Stenstrom R, Harris D. A pharma coeconomic study of traditional anticoagulation versus direct oral anticoagulation for the treatment of venous thromboembolism in the emergency department. CJEM. 2016;18:340-8.

Muñoz A, Gallardo E, Agnelli G, Crespo C, Forghani M, Arumi D, et al. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. J Med Econ. 2022;25:840-7.